William Blair Reiterates “Outperform” Rating for Medpace (NASDAQ:MEDP)

William Blair reaffirmed their outperform rating on shares of Medpace (NASDAQ:MEDP) in a research report released on Tuesday, Benzinga reports. William Blair also issued estimates for Medpace’s FY2024 earnings at $11.83 EPS, Q1 2025 earnings at $2.92 EPS, Q3 2025 earnings at $3.18 EPS, Q4 2025 earnings at $3.19 EPS and FY2025 earnings at $12.35 EPS.

A number of other research analysts also recently weighed in on MEDP. Robert W. Baird decreased their price target on Medpace from $430.00 to $413.00 and set an “outperform” rating for the company in a research note on Friday, September 20th. Redburn Atlantic assumed coverage on Medpace in a research report on Monday, October 14th. They issued a “buy” rating and a $404.00 price objective for the company. Guggenheim cut their price objective on Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a research report on Wednesday, July 24th. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and cut their price objective for the company from $415.00 to $345.00 in a research report on Wednesday, September 25th. Finally, Deutsche Bank Aktiengesellschaft cut their price objective on Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a research report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $380.00.

Medpace Stock Down 0.6 %

MEDP stock opened at $328.08 on Tuesday. The business has a 50 day moving average price of $352.59 and a two-hundred day moving average price of $381.83. The company has a market cap of $10.16 billion, a price-to-earnings ratio of 33.44, a P/E/G ratio of 1.77 and a beta of 1.35. Medpace has a twelve month low of $239.00 and a twelve month high of $459.77.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.24. The firm had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The business’s revenue was up 8.3% compared to the same quarter last year. During the same period last year, the company earned $2.22 earnings per share. On average, equities research analysts anticipate that Medpace will post 11.64 EPS for the current fiscal year.

Institutional Trading of Medpace

Several hedge funds have recently added to or reduced their stakes in MEDP. Westwind Capital lifted its holdings in Medpace by 800.1% during the 2nd quarter. Westwind Capital now owns 380,929 shares of the company’s stock worth $156,886,000 after purchasing an additional 338,610 shares during the last quarter. Findlay Park Partners LLP bought a new position in Medpace during the 1st quarter worth $90,247,000. Clearbridge Investments LLC increased its stake in Medpace by 302.4% during the 1st quarter. Clearbridge Investments LLC now owns 260,411 shares of the company’s stock worth $105,245,000 after acquiring an additional 195,698 shares during the period. Renaissance Technologies LLC increased its stake in Medpace by 38.3% during the 2nd quarter. Renaissance Technologies LLC now owns 443,588 shares of the company’s stock worth $182,692,000 after acquiring an additional 122,800 shares during the period. Finally, AQR Capital Management LLC increased its stake in Medpace by 62.3% during the 2nd quarter. AQR Capital Management LLC now owns 310,650 shares of the company’s stock worth $127,941,000 after acquiring an additional 119,257 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.